Last reviewed · How we verify

RENESSANS , INTERFERON ALPHA 2b, Ribavirin — Competitive Intelligence Brief

RENESSANS , INTERFERON ALPHA 2b, Ribavirin (RENESSANS , INTERFERON ALPHA 2b, Ribavirin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral combination therapy. Area: Virology/Hepatology.

phase 3 Antiviral combination therapy Hepatitis C virus NS5B RNA polymerase; interferon alpha receptor signaling Virology/Hepatology Biologic Live · refreshed every 30 min

Target snapshot

RENESSANS , INTERFERON ALPHA 2b, Ribavirin (RENESSANS , INTERFERON ALPHA 2b, Ribavirin) — MTI Medical Private Limited, Pakistan. This combination therapy uses interferon alpha-2b to enhance antiviral immune response and ribavirin to inhibit viral replication, targeting hepatitis C virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
RENESSANS , INTERFERON ALPHA 2b, Ribavirin TARGET RENESSANS , INTERFERON ALPHA 2b, Ribavirin MTI Medical Private Limited, Pakistan phase 3 Antiviral combination therapy Hepatitis C virus NS5B RNA polymerase; interferon alpha receptor signaling
Peg-IFN + WB RBV for 16 weeks Peg-IFN + WB RBV for 16 weeks National Taiwan University Hospital marketed Antiviral combination therapy Interferon-alpha receptor; HCV RNA polymerase
Pegylated interferon and ribavirin Pegylated interferon and ribavirin Pacific Health Foundation marketed Antiviral combination therapy Interferon-alpha receptor; Hepatitis C virus RNA-dependent RNA polymerase
Peg-IFN + WB RBV for 48 weeks Peg-IFN + WB RBV for 48 weeks National Taiwan University Hospital marketed Antiviral combination therapy Interferon-alpha receptor; HCV RNA polymerase
Quadruple therapy Quadruple therapy Sherief Abd-Elsalam marketed Antiviral combination therapy
Ribavirin, Peg interferon alfa 2b Ribavirin, Peg interferon alfa 2b Brooke Army Medical Center marketed Antiviral combination therapy HCV RNA-dependent RNA polymerase; interferon-alpha receptor
Peg-IFN + RBV Peg-IFN + RBV National Taiwan University Hospital marketed Antiviral combination therapy Interferon-alpha receptor; HCV RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral combination therapy class)

  1. Kaohsiung Medical University Chung-Ho Memorial Hospital · 6 drugs in this class
  2. National Taiwan University Hospital · 6 drugs in this class
  3. Casa Sollievo della Sofferenza IRCCS · 1 drug in this class
  4. Hepatitis Resource Network · 1 drug in this class
  5. Hospices Civils de Lyon · 1 drug in this class
  6. MTI Medical Private Limited, Pakistan · 1 drug in this class
  7. Pacific Health Foundation · 1 drug in this class
  8. RedHill Biopharma Limited · 1 drug in this class
  9. Sherief Abd-Elsalam · 1 drug in this class
  10. The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RENESSANS , INTERFERON ALPHA 2b, Ribavirin — Competitive Intelligence Brief. https://druglandscape.com/ci/renessans-interferon-alpha-2b-ribavirin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: